Get the Stockscreener App
0.341
15.35%
-0.059
Indaptus Therapeutics Inc stock is traded at $0.341, with a volume of 762.42K.
It is down -15.35% in the last 24 hours and down -26.39% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$0.40
Open:
$0.34
24h Volume:
762.42K
Relative Volume:
1.27
Market Cap:
$5.45M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-0.1853
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-8.24%
1M Performance:
-26.39%
6M Performance:
-66.80%
1Y Performance:
-86.35%
1-Day Range:
$0.3258
$0.3584
1-Week Range:
$0.31
$0.40
52-Week Range:
$0.31
$2.8888
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
0.34 | 6.08M | 0 | -15.42M | -13.41M | -1.84 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.39 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.57 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.20 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Indaptus Therapeutics (NASDAQ:INDP) Trading Down 1.9% – What’s Next? - Defense World
Indaptus Therapeutics (INDP) Advances Clinical Trials and Expands Patent Portfolio | INDP Stock News - GuruFocus
INDP Faces Funding Needs as Cash Reserves Decline | INDP Stock News - GuruFocus
Indaptus Therapeutics reports Q1 EPS (32c) vs. (45c) last year - TipRanks
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 2025 Financial Results and Corporate Update - TradingView
Indaptus Therapeutics, Inc. SEC 10-Q Report - TradingView
Indaptus Launches Key Cancer Drug Combination Trial as Q1 Cash Drops to $3.9MWhat's Next? - Stock Titan
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - marketscreener.com
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - The Manila Times
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update - Defense World
Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times
Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion - Stock Titan
Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com
Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients - Marketscreener.com
Indaptus reports progress in Decoy20 cancer therapy trial - Investing.com India
Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial - Stock Titan
Indaptus tests new cancer therapy combination By Investing.com - Investing.com Australia
Indaptus tests new cancer therapy combination - Investing.com India
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times
Groundbreaking Cancer Trial: Indaptus Combines Novel Decoy20 with Checkpoint Inhibitor - StockTitan
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Benzinga
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Drop in Short Interest - Defense World
INDAPTUS THERAPEUTICS Earnings Results: $INDP Reports Quarterly Earnings - Nasdaq
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics reports full-year loss of $1.61 per share -March 13, 2025 at 07:40 am EDT - Marketscreener.com
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results - TradingView
Indaptus Therapeutics Enrolls Over 20 Patients in Phase 1 Trial of Decoy20, Achieving Key Clinical Milestone - Nasdaq
Indaptus Therapeutics, Inc. SEC 10-K Report - TradingView
Registration Is Now Open For Tribe Public’s Webinar Event - GlobeNewswire
Registration Is Now Open For Tribe Public's Webinar Event 'Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 - The Manila Times
Registration Is Now Open For Tribe Public’s Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - Nasdaq
Indaptus Therapeutics extends patent portfolio in China, Japan, and Israel - BioSpectrum Asia
Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments - Marketscreener.com
Indaptus secures new patents in Asia and Israel for Decoy platform By Investing.com - Investing.com South Africa
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - The Manila Times
Indaptus secures new patents in Asia and Israel for Decoy platform - Investing.com
Indaptus Therapeutics Secures New Patent Approvals in China, Japan, and Israel for Decoy Platform in HIV and HBV Treatment - Nasdaq
Can Indaptus' New Asian Patents Transform Its Position in the $4B Hepatitis B Market? - StockTitan
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - The Manila Times
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - StockTitan
Indaptus Therapeutics (NASDAQ:INDP) Trading Down 0.6% – Should You Sell? - Defense World
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):